Treatment outcome after radiochemotherapy in anal cancer patients staged with 18F-FDG-PET-CT

[1]  N. Lawrentschuk,et al.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.

[2]  V. Gebski,et al.  Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Simone,et al.  The Utility of PET/Computed Tomography for Radiation Oncology Planning, Surveillance, and Prognosis Prediction of Gastrointestinal Tumors. , 2020, PET clinics.

[4]  J. Lagendijk,et al.  Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer , 2019, European Radiology.

[5]  C. Coolens,et al.  A prospective, multi-centre trial of multi-parametric MRI as a biomarker in anal carcinoma. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  C. Oldmeadow,et al.  FDG-PET parameters predict for recurrence in anal cancer – results from a prospective, multicentre clinical trial , 2019, Radiation Oncology.

[7]  W. Weber,et al.  Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines , 2019, BMC Cancer.

[8]  C. Rödel,et al.  Chemoradiotherapy for anal cancer: are we as good as we think? , 2019, Strahlentherapie und Onkologie.

[9]  W. Vach,et al.  Practice-based evidence for the clinical benefit of PET/CT—results of the first oncologic PET/CT registry in Germany , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  D. Jonker,et al.  PET imaging in anal canal cancer: a systematic review and meta-analysis. , 2017, The British journal of radiology.

[11]  D. Zwahlen,et al.  PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer , 2017, Acta oncologica.

[12]  P. Parikh,et al.  Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus , 2017, Advances in radiation oncology.

[13]  J. Kaptein,et al.  Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma. , 2016, Practical radiation oncology.

[14]  F. Mottaghy,et al.  Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. , 2016, European journal of radiology.

[15]  Peter Hoskin,et al.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment , 2016, Nature Reviews Clinical Oncology.

[16]  C. McConkey,et al.  PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. , 2016, The New England journal of medicine.

[17]  M. Solomon,et al.  The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis , 2015, Annals of Surgical Oncology.

[18]  P. Smolewski,et al.  The Role of Radiotherapy in Hodgkin's Lymphoma: What Has Been Achieved during the Last 50 Years? , 2015, BioMed research international.

[19]  Robert Jeraj,et al.  Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response , 2013, The Journal of Nuclear Medicine.

[20]  J. Ledermann,et al.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. , 2013, The Lancet. Oncology.

[21]  B. Loo,et al.  Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal , 2013, Journal of Nuclear Medicine.

[22]  Karin Haustermans,et al.  Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. , 2012, International journal of radiation oncology, biology, physics.

[23]  P. Grigsby,et al.  Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  P. Grigsby.  FDG-PET/CT: new horizons in anal cancer. , 2009, Gastroenterologie clinique et biologique.

[25]  C. Ko,et al.  Outcomes and Prognostic Factors for Squamous-Cell Carcinoma of the Anal Canal: Analysis of Patients From the National Cancer Data Base , 2009, Diseases of the colon and rectum.

[26]  A. Hogg,et al.  The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer , 2009, British Journal of Cancer.

[27]  V. Khoo,et al.  Assessing the impact of FDG-PET in the management of anal cancer. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  Charles R. Thomas,et al.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. , 2008, JAMA.

[29]  J. Zuger,et al.  Positron Emission Tomography for Pretreatment Staging and Posttreatment Evaluation in Cancer of the Anal Canal , 2005, Molecular Imaging and Biology.

[30]  S. Schwartz,et al.  Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973–2000 , 2004, Cancer.

[31]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[32]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[33]  H. Bartelink,et al.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[35]  D. Jonker,et al.  SySteMAtiC Review Pet imaging in anal canal cancer: a systematic review and meta-analysis , 2017 .

[36]  A. Lièvre,et al.  Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  C. Perotti,et al.  Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival , 2015, La radiologia medica.